scholarly journals Withdrawal: The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for Down syndrome.

2020 ◽  
Vol 295 (10) ◽  
pp. 3392-3392
Author(s):  
Stefania Trazzi ◽  
Claudia Fuchs ◽  
Emanuele Valli ◽  
Giovanni Perini ◽  
Renata Bartesaghi ◽  
...  
2013 ◽  
Vol 288 (29) ◽  
pp. 20817-20829 ◽  
Author(s):  
Stefania Trazzi ◽  
Claudia Fuchs ◽  
Emanuele Valli ◽  
Giovanni Perini ◽  
Renata Bartesaghi ◽  
...  

Intellectual disability in Down syndrome (DS) appears to be related to severe proliferation impairment during brain development. Recent evidence shows that it is not only cellular proliferation that is heavily compromised in DS, but also cell fate specification and dendritic maturation. The amyloid precursor protein (APP), a gene that is triplicated in DS, plays a key role in normal brain development by influencing neural precursor cell proliferation, cell fate specification, and neuronal maturation. APP influences these processes via two separate domains, the APP intracellular domain (AICD) and the soluble secreted APP. We recently found that the proliferation impairment of neuronal precursors (NPCs) from the Ts65Dn mouse model for DS was caused by derangement of the Shh pathway due to overexpression of patched1(Ptch1), its inhibitory regulator. Ptch1 overexpression was related to increased levels within the APP/AICD system. The overall goal of this study was to determine whether APP contributes to neurogenesis impairment in DS by influencing in addition to proliferation, cell fate specification, and neurite development. We found that normalization of APP expression restored the reduced neuronogenesis, the increased astrogliogenesis, and the reduced neurite length of trisomic NPCs, indicating that APP overexpression underpins all aspects of neurogenesis impairment. Moreover, we found that two different domains of APP impair neuronal differentiation and maturation in trisomic NPCs. The APP/AICD system regulates neuronogenesis and neurite length through the Shh pathway, whereas the APP/secreted AP system promotes astrogliogenesis through an IL-6-associated signaling cascade. These results provide novel insight into the mechanisms underlying brain development alterations in DS.


2009 ◽  
Vol 110 (6) ◽  
pp. 1818-1827 ◽  
Author(s):  
Jennifer H. K. Choi ◽  
Jason D. Berger ◽  
Matthew J. Mazzella ◽  
Jose Morales-Corraliza ◽  
Anne M. Cataldo ◽  
...  

Hippocampus ◽  
2003 ◽  
Vol 13 (8) ◽  
pp. 905-914 ◽  
Author(s):  
Ann-Charlotte Granholm ◽  
Linda Sanders ◽  
Hyemyung Seo ◽  
Ling Lin ◽  
Kerstin Ford ◽  
...  

2020 ◽  
pp. 1-16
Author(s):  
Margaret Ryan ◽  
Valerie T.Y. Tan ◽  
Nasya Thompson ◽  
Diane Guévremont ◽  
Bruce G. Mockett ◽  
...  

Background: Secreted amyloid precursor protein-alpha (sAPPα) can enhance memory and is neurotrophic and neuroprotective across a range of disease-associated insults, including amyloid-β toxicity. In a significant step toward validating sAPPα as a therapeutic for Alzheimer’s disease (AD), we demonstrated that long-term overexpression of human sAPPα (for 8 months) in a mouse model of amyloidosis (APP/PS1) could prevent the behavioral and electrophysiological deficits that develop in these mice. Objective: To explore the underlying molecular mechanisms responsible for the significant physiological and behavioral improvements observed in sAPPα-treated APP/PS1 mice. Methods: We assessed the long-term effects on the hippocampal transcriptome following continuous lentiviral delivery of sAPPα or empty-vector to male APP/PS1 mice and wild-type controls using Affymetrix Mouse Transcriptome Assays. Data analysis was carried out within the Affymetrix Transcriptome Analysis Console and an integrated analysis of the resulting transcriptomic data was performed with Ingenuity Pathway analysis (IPA). Results: Mouse transcriptome assays revealed expected AD-associated gene expression changes in empty-vector APP/PS1 mice, providing validation of the assays used for the analysis. By contrast, there were specific sAPPα-associated gene expression profiles which included increases in key neuroprotective genes such as Decorin, betaine-GABA transporter, and protocadherin beta-5, subsequently validated by qRT-PCR. An integrated biological pathways analysis highlighted regulation of GABA receptor signaling, cell survival, and inflammatory responses. Furthermore, upstream gene regulatory analysis implicated sAPPα activation of Interleukin-4, which can counteract inflammatory changes in AD. Conclusion: This study identified key molecular processes that likely underpin the long-term neuroprotective and therapeutic effects of increasing sAPPα levels in vivo


2015 ◽  
Vol 136 (3) ◽  
pp. 497-502 ◽  
Author(s):  
Annica Rönnbäck ◽  
Pavel. F. Pavlov ◽  
Mansorah Mansory ◽  
Prisca Gonze ◽  
Nicolas Marlière ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document